Abstract
Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.
| Original language | English |
|---|---|
| Pages (from-to) | 122-127 |
| Number of pages | 6 |
| Journal | Clinical Colorectal Cancer |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Colon cancer
- ERCC1
- In vitro chemosensitivity test
- Peritoneal carcinomatosis
- Response prediction
- TS
ASJC Scopus subject areas
- Oncology
- Gastroenterology
Cite this
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. / Arienti, Chiara; Tesei, Anna; Verdecchia, Giorgio Maria; Framarini, Massimo; Virzì, Salvatore; Grassi, Antonio; Scarpi, Emanuela; Turci, Livia; Silvestrini, Rosella; Amadori, Dino; Zoli, Wainer.
In: Clinical Colorectal Cancer, Vol. 12, No. 2, 2013, p. 122-127.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer
AU - Arienti, Chiara
AU - Tesei, Anna
AU - Verdecchia, Giorgio Maria
AU - Framarini, Massimo
AU - Virzì, Salvatore
AU - Grassi, Antonio
AU - Scarpi, Emanuela
AU - Turci, Livia
AU - Silvestrini, Rosella
AU - Amadori, Dino
AU - Zoli, Wainer
PY - 2013
Y1 - 2013
N2 - Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.
AB - Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.
KW - Colon cancer
KW - ERCC1
KW - In vitro chemosensitivity test
KW - Peritoneal carcinomatosis
KW - Response prediction
KW - TS
UR - http://www.scopus.com/inward/record.url?scp=84876842335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876842335&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2012.11.006
DO - 10.1016/j.clcc.2012.11.006
M3 - Article
C2 - 23332421
AN - SCOPUS:84876842335
VL - 12
SP - 122
EP - 127
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
SN - 1533-0028
IS - 2
ER -